Clinical trials data
Verbal Learning in Parkinson's disease trials: 61 registered studies
Every registered Parkinson's disease study on ClinicalTrials.gov that names Verbal Learning in an outcome measure: how often it is a primary outcome, the tests named with it, how large the studies are and when they measure it.
- Registered Parkinson's disease studies name it in an outcome measure
- 61
- Name it in a primary outcome, 36%
- 22 of 61
Tests named in the same studies
- 1
Verbal Fluency33 studies, 10 as a primary outcome
- 2
Trail Making Test32 studies, 10 as a primary outcome
- 3
Stroop Color-Word Test21 studies, 7 as a primary outcome
- 4
Digit Span Test21 studies, 4 as a primary outcome
- 5
Line Angle Matching17 studies, 5 as a primary outcome
- 6
Picture Naming Test16 studies, 4 as a primary outcome
- 7
Category Fluency12 studies, 5 as a primary outcome
- 8
Card Sorting Test (Berg)10 studies, 5 as a primary outcome
- 9
Complex Figure Copy and Recall10 studies, 2 as a primary outcome
- 10
Symbol Coding7 studies, 1 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
Studies by start year
A test as a primary outcomeOnly in secondary or other outcomes
Show as a table
| Start year | Studies | A test as a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 2 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 2 | 2 |
| 2012 | 3 | 2 |
| 2013 | 1 | 1 |
| 2014 | 3 | 0 |
| 2015 | 2 | 0 |
| 2016 | 2 | 0 |
| 2017 | 6 | 2 |
| 2018 | 4 | 2 |
| 2019 | 6 | 3 |
| 2020 | 3 | 2 |
| 2021 | 3 | 2 |
| 2022 | 5 | 1 |
| 2023 | 2 | 1 |
| 2024 | 5 | 2 |
| 2025 | 5 | 1 |
| 2026 | 6 | 1 |
Phases and study sizes
By phase
- Early phase 12 studies, 0 as a primary outcome
- Phase 12 studies, 0 as a primary outcome
- Phase 1/21 studies, 1 as a primary outcome
- Phase 211 studies, 1 as a primary outcome
- Phase 31 studies, 1 as a primary outcome
- Phase 42 studies, 1 as a primary outcome
- Not applicable29 studies, 10 as a primary outcome
- Observational13 studies, 8 as a primary outcome
Participants per study
- Phase 274 median, 36 to 114
- Not applicable32 median, 23 to 50
- Observational71 median, 48 to 137
Show as a table
| Phase | Studies with a size | Median | Middle half |
|---|---|---|---|
| Phase 2 | 11 | 74 | 36 to 114 |
| Not applicable | 29 | 32 | 23 to 50 |
| Observational | 12 | 71 | 48 to 137 |
When Parkinson's disease trials measure it
Latest time point of each outcome
- Within a day12 outcomes, 6 as a primary outcome
- Up to 4 weeks10 outcomes, 3 as a primary outcome
- 1 to 3 months10 outcomes, 2 as a primary outcome
- 3 to 6 months14 outcomes, 5 as a primary outcome
- 6 to 12 months4 outcomes, 3 as a primary outcome
- 1 to 2 years3 outcomes, 0 as a primary outcome
- Over 2 years4 outcomes, 1 as a primary outcome
- No duration given4 outcomes, 2 as a primary outcome
A test as a primary outcomeOnly in secondary or other outcomes
57 of the 61 outcome measures give a duration. A single visit counts as within a day.
Status, results, interventions and countries
Status
- Recruiting15 studies, 4 as a primary outcome
- Not yet recruiting2 studies, 1 as a primary outcome
- Active, not recruiting2 studies, 1 as a primary outcome
- Completed26 studies, 11 as a primary outcome
- Stopped early6 studies, 2 as a primary outcome
- Status unknown10 studies, 3 as a primary outcome
What they test
- Behavioral13 studies, 4 as a primary outcome
- Drug16 studies, 4 as a primary outcome
- Device13 studies, 5 as a primary outcome
- Dietary supplement1 studies, 0 as a primary outcome
- Procedure3 studies, 1 as a primary outcome
- Diagnostic test3 studies, 3 as a primary outcome
- Biological3 studies, 1 as a primary outcome
- Radiation2 studies, 2 as a primary outcome
- Genetic1 studies, 1 as a primary outcome
- Other14 studies, 7 as a primary outcome
- None given5 studies, 2 as a primary outcome
Intervention types as registered. A study can list several; observational studies often list none.
Where their sites are
- United States28 studies, 12 as a primary outcome
- Netherlands6 studies, 0 as a primary outcome
- Sweden6 studies, 1 as a primary outcome
- Germany4 studies, 0 as a primary outcome
- Italy4 studies, 3 as a primary outcome
- Switzerland4 studies, 2 as a primary outcome
- China3 studies, 1 as a primary outcome
- France3 studies, 0 as a primary outcome
- Spain3 studies, 1 as a primary outcome
- United Kingdom3 studies, 0 as a primary outcome
- Canada2 studies, 0 as a primary outcome
- Czechia2 studies, 0 as a primary outcome
20 countries in all. A study with sites in several counts in each; 0 list no site.
Reported results
Completed studies with results posted on ClinicalTrials.gov, a results paper the registry links to the study, or both.
Completed Parkinson's disease studies that name Verbal Learning: 16 of 26, 62%
Every completed study with a cognitive outcome: 3,626 of 7,953, 46%
| Results | Completed Parkinson's disease studies that name Verbal Learning | Every completed study |
|---|---|---|
| Results on ClinicalTrials.gov and a paper | 5, 19% | 776, 10% |
| Results on ClinicalTrials.gov only | 8, 31% | 1,139, 14% |
| A results paper only | 3, 12% | 1,711, 22% |
| Neither | 10, 38% | 4,327, 54% |
The 61 studies
61 studies match. 22 name Verbal Learning in a primary outcome. Median size 45 participants. Median time to the primary outcome: 11 weeks.
Loading 61 studies; the filters turn on when they arrive.
2026 is partly planned starts.
Show as a table
| Start year | Studies | As a primary outcome |
|---|---|---|
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 2 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 2 | 2 |
| 2012 | 3 | 2 |
| 2013 | 1 | 1 |
| 2014 | 3 | 0 |
| 2015 | 2 | 0 |
| 2016 | 2 | 0 |
| 2017 | 6 | 2 |
| 2018 | 4 | 2 |
| 2019 | 6 | 3 |
| 2020 | 3 | 2 |
| 2021 | 3 | 2 |
| 2022 | 5 | 1 |
| 2023 | 2 | 1 |
| 2024 | 5 | 2 |
| 2025 | 5 | 1 |
| 2026 | 6 | 1 |
Library tests named most
Largest condition groups
Phases
Participants
Lead sponsor: industry 4, other 57. Interventional 48, observational 13.
As a primary outcomeSecondary or other outcomeVerbal Learning
The studies, newest registration first
Each number opens the study's record on ClinicalTrials.gov.
| Study | Start | Phase | Conditions | Participants | Lead sponsor | Status | Library tests named, with the latest time point |
|---|---|---|---|---|---|---|---|
| NCT07651085 | Start2024 | PhaseObservational | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Parkinson's disease, Sleep and sleep disorders | Participants65 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT07610369 | Start2026 | PhasePhase 2 | ConditionsParkinson's disease, Depression and bipolar disorder | Participants40 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07540325 | Start2026 | PhaseObservational | ConditionsParkinson's disease | Participants30 | Lead sponsorOther | StatusNot yet recruiting | Library tests named
|
| NCT07355842 | Start2026 | PhaseNot applicable | ConditionsParkinson's disease, Sleep and sleep disorders | Participants80 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07312110 | Start2026 | PhasePhase 2 | ConditionsParkinson's disease | Participants100 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07271927 | Start2025 | PhaseNot applicable | ConditionsParkinson's disease | Participants15 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07262658 | Start2022 | PhaseObservational | ConditionsParkinson's disease | Participants40 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT07214974 | Start2026 | PhaseEarly phase 1 | ConditionsDementia and Alzheimer's, Mild cognitive impairment, Parkinson's disease | Participants600 | Lead sponsorIndustry | StatusNot yet recruiting | Library tests named
|
| NCT07154511 | Start2025 | PhasePhase 1/2 | ConditionsDementia and Alzheimer's, Parkinson's disease | Participants45 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT07055087 | Start2026 | PhasePhase 2 | ConditionsParkinson's disease | Participants120 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06906276 | Start2025 | PhaseObservational | ConditionsParkinson's disease, Aging, frailty and exercise | Participants30 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06901869 | Start2025 | PhaseObservational | ConditionsParkinson's disease, Aging, frailty and exercise | Participants50 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06782724 | Start2025 | PhasePhase 2 | ConditionsParkinson's disease, Multiple sclerosis, Depression and bipolar disorder, Lung disease | Participants108 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06688357 | Start2019 | PhaseNot applicable | ConditionsParkinson's disease | Participants23 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT06665113 | Start2024 | PhaseNot applicable | ConditionsParkinson's disease | Participants12 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06580977 | Start2024 | PhaseNot applicable | ConditionsParkinson's disease | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06400017 | Start2024 | PhaseNot applicable | ConditionsParkinson's disease | Participants60 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT06399731 | Start2024 | PhaseNot applicable | ConditionsMild cognitive impairment, Parkinson's disease | Participants20 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05819008 | Start2023 | PhaseObservational | ConditionsStroke, Brain injury and concussion, Parkinson's disease, Multiple sclerosis, Cancer, Epilepsy | Participants350 | Lead sponsorOther | StatusRecruiting | Library tests named
|
| NCT05635409 | Start2022 | PhasePhase 1 | ConditionsParkinson's disease | Participants8 | Lead sponsorOther | StatusActive, not recruiting | Library tests named
|
| NCT05514379 | Start2022 | PhaseNot applicable | ConditionsParkinson's disease | Participants50 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05506891 | Start2023 | PhasePhase 2 | ConditionsParkinson's disease | Participants40 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
| NCT05333549 | Start2022 | PhasePhase 2 | ConditionsParkinson's disease | Participants15 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT05218213 | Start2022 | PhaseObservational | ConditionsParkinson's disease, Aging, frailty and exercise | Participants133 | Lead sponsorOther | StatusCompleted | Library tests named
|
| NCT04878679 | Start2021 | PhaseNot applicable | ConditionsParkinson's disease | Participants36 | Lead sponsorOther | StatusStatus unknown | Library tests named
|
Questions, answered from the data
How many Parkinson's disease trials use Verbal Learning?
61 registered Parkinson's disease studies on ClinicalTrials.gov name it in an outcome measure, 22 of them in a primary outcome: 7% of the condition's 892 studies with a cognitive outcome, against 11% of all of them. It is the 5th most named test in Parkinson's disease trials.
Which tests do Parkinson's disease trials use with Verbal Learning?
Verbal Fluency (33 studies), the Trail Making Test (32 studies) and the Stroop Color-Word Test (21 studies).
How many participants do phase 2 Parkinson's disease trials that use Verbal Learning enroll?
Half of the phase 2 studies that name it enroll 74 participants or fewer, and the middle half enroll 36 to 114. 11 of them give a size.
When do Parkinson's disease trials measure Verbal Learning?
Half of the primary outcomes that name Verbal Learning are measured within 11 weeks of the start, and the middle half from the first day to 6 months. 20 primary outcomes give a duration.
How many completed Parkinson's disease trials that use Verbal Learning have reported results?
16 of the 26 completed studies that name it, 62%, have reported results: 13 posted them on ClinicalTrials.gov, 8 have a results paper linked to the registry record, and 5 did both. The other 10 show neither. Of all completed studies with a cognitive outcome, 46% have reported results.
How the studies are counted
For each test family, the census runs ClinicalTrials.gov's own outcome search for the family's names and reads every study first posted by the day the family was counted. These studies were read on 10 November 2026. A study counts once on a page, however many tests it names. Counts for a test cover every version of the task under any of its names, so a page can count studies that used a commercial version.
The census adds two things to each record and changes nothing in it: which outcome list names the test (primary, then secondary, then other), and the condition groups, matched on the study's condition names and MeSH terms. A study can fall in several groups; one whose only condition is cognitive impairment or decline falls in “Cognitive impairment and decline”. Studies that name only instruments outside the library count in every total and share but are not listed.
A second read on 10 November 2026 added each study's overall status, whether results are posted, its intervention types, the countries of its sites and the time frame of the outcome that names each test. A time frame counts by the latest time point it names: “Baseline, 12 and 24 weeks” is 24 weeks, a single visit is within a day, and one that names no duration, such as “end of treatment”, is left out of the timings.
A third read on 10 November 2026 added the papers the registry links to each study: those its sponsor lists as reporting results, and those PubMed links to it through the study's NCT number. A study has a results paper when one of them came out in or after the month of its primary completion and PubMed does not class it as a protocol, review or comment. A paper that never gives the NCT number is not linked, so some studies counted as reporting neither did publish.
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine, which does not endorse these pages. Every study line is in the data release 2.1.0, and the explorer's own file is clinical-trials-studies.json.
The census counts Verbal Learning and Grocery Trip Game as one test family, so this page counts their studies together.
Run Verbal Learning in your trial
Choose tests with a record in registered trials, and run them in a browser at every site, on the same version each visit.